Inventor of synthetic Interferon discusses potential against COVID-19

An interview with Founder & Chief Scientific Officer William Stimson in Drug Discovery World. Please read the interview below.

More To Explore


ILC Therapeutics strengthens team to accelerate development of COVID-19 drug

Pioneering biotech company strengthened by senior appointments to bolster capabilities in research, product development and clinical trials of COVID-19 drug.  Company ready to accelerate the development of Alfacyte™ – ILC’s lead hybrid interferon designed to combat viral infections including COVID-19. ILC is delighted to announce that it has made two

Read More »

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email